Tirzepatide has shown significant weight loss and cardiometabolic benefits for patients with diabetes and overweight. Early responders who lost 5% or more weight in 8 weeks saw the most benefits. Data from the SURMOUNT trials showed that early responders had greater weight loss and improvements in parameters such as blood pressure and cholesterol compared to non-early responders. This analysis demonstrates the importance of early response to treatment and personalized therapeutic goals. Tirzepatide treatment, regardless of early response, led to significant reductions in weight and cardiometabolic parameters at week 72. The SURMOUNT trials were funded by Eli Lilly.
Source link
Early weight loss with tirzepatide predictive of larger cardiometabolic benefits later on
